FULL TEST
TEST BANK FOR PHARMACOTHERAPEUTICS FOR
ADVANCED PRACTICE A PRACTICAL APPROACH 5TH
EDITION BY VIRGINIA POOLE ARCANGELO; ANDREW
PETERSON; VERONICA WILBUR; JENNIFER A. REINHOLD
PRINTED PDF I ORIGINAL DIRECTLY FROM THE PUBLISHER I 1OO%
VERIFIED ANSWERS ] DOWNLOAD IMMEDIATELY AFTER THE ORDER
['LIZ)LI12%5IL!
[LI.GIL
Complete Test bank, All Chapters are included.
For more Test banks, ATI, HES! exams, and more contact us.
, Table of content
Chapter I Issues for the Practitioner in Drug Therapy
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5 Pharmacotherapy Principles in Older Adults
Chapter 6 Principles of Antimicrobial Therapy
Chapter 7 Pharmacogenomies
Chapter 8 The Economics of Pharmacotherapeutics
Chapter 9 Pharmacotherapy of Pain Management
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11 Cannabis and Pain Management
Chapter 12 Contact Dermatitis
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14 Psoriasis
Chapter I5 Acne Vulgaris and Rosacea
Chapter 16 Ophthalmic Disorders
Chapter I7 Otitis Media and Otitis Externa
Chapter I8 Hypertension
Chapter I9 Hyperlipidemia
Chapter 20 Chronic Stable Angina and Myocardial Infarction
Chapter 2I Heart Failure
Chapter 22 Arrhythmias
Chapter 23 Respiratory Infections
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25 Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27 Liver Diseases
Chapter 28 Urinary Tract Infection
Chapter 29 Prostatic Disorders and Erectile Dysfunction
Chapter 30 Overactive Bladder
Chapter 3I Sexually Transmitted Infections
Chapter 32 Osteoarthritis and Gout
Chapter 33 Osteoporosis
Chapter 34 Rheumatoid Arthritis
Chapter 35 Headaches
Chapter 36 Seizure Disorders
Chapter 37 Alzheimer's Disease
Chapter 38 Parkinson's Disease
Chapter 39 Major Depressive Disorder and Bipolar Disorders
Chapter 40 Anxiety Disorders
Chapter 41 Sleep Disorders
Chapter 42 Attention Deficit Hyperactivity Disorder
Chapter 43 Substance Use Disorders
Chapter 44 Diabetes Mellitus
Chapter 45 Thyroid and Parathyroid Disorders
,Chapter 46 Allergies and Allergic Reactions
Chapter 47 Human Immunodeficiency Virus
Chapter 48 Organ Transplantation
Chapter 49 Thromboembolic Disorders
Chapter 50 Anemias
Chapter 5l Immunizations
Chapter 52 Smoking Cessation
Chapter 53 Weight Loss
Chapter 54 Contraception
Chapter 55 Menopause
Chapter 56 Vaginitis
, lOMoAR cPSD| 21007614
lOMoAR cPSD| 21007614
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, lOMoAR cPSD| 21007614
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A fpatient's fnutritional fintake fand flab fwork freflects fhypoalbuminemia. fThis fis
fcritical fto fprescribing f because:
A. Distribution fof fdrugs fto ftarget ftissue fmay fbe faffected
B. The fsolubility fof fthe fdrug fwill fnot fmatch fthe fsite fof fabsorption
C. There fwill fbe fless ffree fdrug favailable fto fgenerate fan feffect
D. Drugs fbound fto falbumin fare freadily fexcreted fby fthe fkidney
ANS: f A PTS: f 1
2. Drugs fthat fhave fa fsignificant ffirst-pass feffect:
A. Must fbe fgiven fby fthe fenteral f(oral) froute fonly
B. Bypass fthe fhepatic fcirculation
C. Are frapidly fmetabolized fby fthe fliver fand fmay fhave flittle fif fany fdesired faction
D. Are fconverted fby fthe fliver fto fmore factive fand ffat-soluble fforms
ANS: f C PTS: f 1
3. The froute fof fexcretion fof fa fvolatile fdrug fwill flikely fbe:
A. The fkidneys
B. The flungs
C. The fbile fand ffeces
D. The fskin
ANS: f B PTS: f 1
4. Medroxyprogesterone f(Depo fProvera) fis fprescribed fIM fto fcreate fa fstorage freservoir
fof fthe fdrug. fStorage freservoirs:
A. Assure fthat fthe fdrug fwill freach fits fintended ftarget ftissue
B. Are fthe freason ffor fgiving floading fdoses
C. Increase fthe flength fof ftime fa fdrug fis favailable fand factive
D. Are fmost fcommon fin fcollagen ftissues
ANS: f C PTS: f 1
5. The fNP fchooses fto fgive fcephalexin fevery f8 fhours fbased fon fknowledge fof fthe fdrug's:
A. Propensity fto fgo fto fthe ftarget freceptor
B. Biological fhalf-life
C. Pharmacodynamics
D. Safety fand fside feffects
ANS: f B PTS: f 1
6. Azithromycin fdosing frequires fthe ffirst fday's fdose fbe ftwice fthose fof fthe fother f4
fdays fof fthe fprescription. fThis f is fconsidered fa f loading fdose. fA f loading fdose:
A. Rapidly fachieves fdrug flevels fin fthe ftherapeutic frange
B. Requires ffour fto ffive fhalf-lives fto fattain
C. Is finfluenced fby frenal ffunction
, lOMoAR cPSD| 21007614
D. Is fdirectly frelated fto fthe fdrug fcirculating fto fthe ftarget ftissues
ANS: f A PTS: f f1
7. The fpoint fin ftime fon fthe fdrug fconcentration fcurve fthat findicates fthe ffirst fsign fof fa
ftherapeutic feffect f is fthe:
A. Minimum fadverse feffect flevel
B. Peak fof faction
C. Onset fof faction
D. Therapeutic frange
ANS: f C PTS: f 1
8. Phenytoin frequires fa ftrough flevel fbe fdrawn. fPeak fand ftrough flevels fare fdone:
A. When fthe fdrug fhas fa fwide ftherapeutic frange
B. When fthe fdrug fwill fbe fadministered ffor fa fshort ftime fonly
C. When fthere fis fa fhigh fcorrelation fbetween fthe fdose fand fsaturation fof freceptor fsites
D. To fdetermine fif fa fdrug fis fin fthe ftherapeutic frange
ANS: f D PTS: f 1
9. A flaboratory fresult findicates fthe fpeak flevel ffor fa fdrug fis fabove fthe
fminimum ftoxic fconcentration. fThis f means fthat fthe:
A. Concentration fwill fproduce ftherapeutic feffects
B. Concentration fwill fproduce fan fadverse fresponse
C. Time fbetween fdoses fmust fbe fshortened
D. Duration fof faction fof fthe fdrug fis ftoo flong
ANS: f B PTS: f 1
10. Drugs fthat fare freceptor fagonists fmay fdemonstrate fwhat fproperty?
A. Irreversible fbinding fto fthe fdrug freceptor fsite
B. Up-regulation fwith fchronic fuse
C. Desensitization for fdown-regulation fwith fcontinuous fuse
D. Inverse frelationship fbetween fdrug fconcentration fand fdrug faction
ANS: f C PTS: f 1
11. Drugs fthat fare freceptor fantagonists, fsuch fas fbeta fblockers, fmay fcause:
A. Down-regulation fof fthe fdrug freceptor
B. An fexaggerated fresponse fif fabruptly fdiscontinued
C. Partial fblockade fof fthe feffects fof fagonist fdrugs
D. An fexaggerated fresponse fto fcompetitive fdrug fagonists
ANS: f B PTS: f 1
12. Factors fthat faffect fgastric fdrug fabsorption finclude:
A. Liver fenzyme factivity
B. Protein-binding fproperties fof fthe fdrug fmolecule
C. Lipid fsolubility fof fthe fdrug
D. Ability fto fchew fand fswallow
ANS: f C PTS: f 1
, lOMoAR cPSD| 21007614
13. Drugs fadministered fvia fintravenous f(IV) froute:
A. Need fto fbe flipid fsoluble fin forder fto fbe feasily fabsorbed
B. Begin fdistribution finto fthe fbody fimmediately
C. Are feasily fabsorbed fif fthey fare fnonionized
D. May fuse fpinocytosis fto fbe fabsorbed
ANS: f B PTS: f 1
14. When fa fmedication fis fadded fto fa fregimen ffor fa fsynergistic feffect, fthe fcombined
feffect fof fthe fdrugs f is:
A. The fsum fof fthe feffects fof feach fdrug findividually
B. Greater fthan fthe fsum fof fthe feffects fof feach fdrug findividually
C. Less fthan fthe feffect fof feach fdrug findividually
D. Not fpredictable, fas fit fvaries fwith feach findividual
ANS: f B PTS: f 1
15. Which fof fthe ffollowing fstatements fabout fbioavailability fis ftrue?
A. Bioavailability fissues fare fespecially fimportant ffor fdrugs fwith fnarrow
ftherapeutic franges for fsustained frelease f mechanisms.
B. All fbrands fof fa fdrug fhave fthe fsame fbioavailability.
C. Drugs fthat fare fadministered fmore fthan fonce fa fday fhave fgreater
fbioavailability fthan fdrugs fgiven fonce fdaily.
D. Combining fan factive fdrug fwith fan finert fsubstance fdoes fnot faffect fbioavailability.
ANS: f A PTS: f 1
16. Which fof fthe ffollowing fstatements fabout fthe fmajor fdistribution fbarriers f(blood-
brain for ffetal-placental) fis ftrue?
A. Water fsoluble fand fionized fdrugs fcross fthese fbarriers frapidly.
B. The fblood-brain fbarrier fslows fthe fentry fof fmany fdrugs finto fand ffrom fbrain fcells.
C. The ffetal-placental fbarrier fprotects fthe ffetus ffrom fdrugs ftaken fby fthe fmother.
D. Lipid fsoluble fdrugs fdo fnot fpass fthese fbarriers fand fare fsafe ffor fpregnant fwomen.
ANS: f B PTS: f 1
17. Drugs fare fmetabolized fmainly fby fthe fliver fvia fPhase fI for fPhase fII freactions. fThe
fpurpose fof fboth fof fthese ftypes fof freactions f is f to:
A. Inactivate fprodrugs fbefore fthey fcan fbe factivated fby ftarget ftissues
B. Change fthe fdrugs fso fthey fcan fcross fplasma fmembranes
C. Change fdrug fmolecules fto fa fform fthat fan fexcretory forgan fcan fexcrete
D. Make fthese fdrugs fmore fionized fand fpolar fto ffacilitate fexcretion
ANS: f C PTS: f 1
18. Once fthey fhave fbeen fmetabolized fby fthe fliver, fthe fmetabolites fmay fbe:
A. More factive fthan fthe fparent fdrug
B. Less factive fthan fthe fparent fdrug
C. Totally f“deactivated” fso fthat fthey fare fexcreted fwithout fany feffect
D. All fof fthe fabove
ANS: f D PTS: f 1
TEST BANK FOR PHARMACOTHERAPEUTICS FOR
ADVANCED PRACTICE A PRACTICAL APPROACH 5TH
EDITION BY VIRGINIA POOLE ARCANGELO; ANDREW
PETERSON; VERONICA WILBUR; JENNIFER A. REINHOLD
PRINTED PDF I ORIGINAL DIRECTLY FROM THE PUBLISHER I 1OO%
VERIFIED ANSWERS ] DOWNLOAD IMMEDIATELY AFTER THE ORDER
['LIZ)LI12%5IL!
[LI.GIL
Complete Test bank, All Chapters are included.
For more Test banks, ATI, HES! exams, and more contact us.
, Table of content
Chapter I Issues for the Practitioner in Drug Therapy
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5 Pharmacotherapy Principles in Older Adults
Chapter 6 Principles of Antimicrobial Therapy
Chapter 7 Pharmacogenomies
Chapter 8 The Economics of Pharmacotherapeutics
Chapter 9 Pharmacotherapy of Pain Management
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11 Cannabis and Pain Management
Chapter 12 Contact Dermatitis
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14 Psoriasis
Chapter I5 Acne Vulgaris and Rosacea
Chapter 16 Ophthalmic Disorders
Chapter I7 Otitis Media and Otitis Externa
Chapter I8 Hypertension
Chapter I9 Hyperlipidemia
Chapter 20 Chronic Stable Angina and Myocardial Infarction
Chapter 2I Heart Failure
Chapter 22 Arrhythmias
Chapter 23 Respiratory Infections
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25 Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27 Liver Diseases
Chapter 28 Urinary Tract Infection
Chapter 29 Prostatic Disorders and Erectile Dysfunction
Chapter 30 Overactive Bladder
Chapter 3I Sexually Transmitted Infections
Chapter 32 Osteoarthritis and Gout
Chapter 33 Osteoporosis
Chapter 34 Rheumatoid Arthritis
Chapter 35 Headaches
Chapter 36 Seizure Disorders
Chapter 37 Alzheimer's Disease
Chapter 38 Parkinson's Disease
Chapter 39 Major Depressive Disorder and Bipolar Disorders
Chapter 40 Anxiety Disorders
Chapter 41 Sleep Disorders
Chapter 42 Attention Deficit Hyperactivity Disorder
Chapter 43 Substance Use Disorders
Chapter 44 Diabetes Mellitus
Chapter 45 Thyroid and Parathyroid Disorders
,Chapter 46 Allergies and Allergic Reactions
Chapter 47 Human Immunodeficiency Virus
Chapter 48 Organ Transplantation
Chapter 49 Thromboembolic Disorders
Chapter 50 Anemias
Chapter 5l Immunizations
Chapter 52 Smoking Cessation
Chapter 53 Weight Loss
Chapter 54 Contraception
Chapter 55 Menopause
Chapter 56 Vaginitis
, lOMoAR cPSD| 21007614
lOMoAR cPSD| 21007614
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, lOMoAR cPSD| 21007614
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A fpatient's fnutritional fintake fand flab fwork freflects fhypoalbuminemia. fThis fis
fcritical fto fprescribing f because:
A. Distribution fof fdrugs fto ftarget ftissue fmay fbe faffected
B. The fsolubility fof fthe fdrug fwill fnot fmatch fthe fsite fof fabsorption
C. There fwill fbe fless ffree fdrug favailable fto fgenerate fan feffect
D. Drugs fbound fto falbumin fare freadily fexcreted fby fthe fkidney
ANS: f A PTS: f 1
2. Drugs fthat fhave fa fsignificant ffirst-pass feffect:
A. Must fbe fgiven fby fthe fenteral f(oral) froute fonly
B. Bypass fthe fhepatic fcirculation
C. Are frapidly fmetabolized fby fthe fliver fand fmay fhave flittle fif fany fdesired faction
D. Are fconverted fby fthe fliver fto fmore factive fand ffat-soluble fforms
ANS: f C PTS: f 1
3. The froute fof fexcretion fof fa fvolatile fdrug fwill flikely fbe:
A. The fkidneys
B. The flungs
C. The fbile fand ffeces
D. The fskin
ANS: f B PTS: f 1
4. Medroxyprogesterone f(Depo fProvera) fis fprescribed fIM fto fcreate fa fstorage freservoir
fof fthe fdrug. fStorage freservoirs:
A. Assure fthat fthe fdrug fwill freach fits fintended ftarget ftissue
B. Are fthe freason ffor fgiving floading fdoses
C. Increase fthe flength fof ftime fa fdrug fis favailable fand factive
D. Are fmost fcommon fin fcollagen ftissues
ANS: f C PTS: f 1
5. The fNP fchooses fto fgive fcephalexin fevery f8 fhours fbased fon fknowledge fof fthe fdrug's:
A. Propensity fto fgo fto fthe ftarget freceptor
B. Biological fhalf-life
C. Pharmacodynamics
D. Safety fand fside feffects
ANS: f B PTS: f 1
6. Azithromycin fdosing frequires fthe ffirst fday's fdose fbe ftwice fthose fof fthe fother f4
fdays fof fthe fprescription. fThis f is fconsidered fa f loading fdose. fA f loading fdose:
A. Rapidly fachieves fdrug flevels fin fthe ftherapeutic frange
B. Requires ffour fto ffive fhalf-lives fto fattain
C. Is finfluenced fby frenal ffunction
, lOMoAR cPSD| 21007614
D. Is fdirectly frelated fto fthe fdrug fcirculating fto fthe ftarget ftissues
ANS: f A PTS: f f1
7. The fpoint fin ftime fon fthe fdrug fconcentration fcurve fthat findicates fthe ffirst fsign fof fa
ftherapeutic feffect f is fthe:
A. Minimum fadverse feffect flevel
B. Peak fof faction
C. Onset fof faction
D. Therapeutic frange
ANS: f C PTS: f 1
8. Phenytoin frequires fa ftrough flevel fbe fdrawn. fPeak fand ftrough flevels fare fdone:
A. When fthe fdrug fhas fa fwide ftherapeutic frange
B. When fthe fdrug fwill fbe fadministered ffor fa fshort ftime fonly
C. When fthere fis fa fhigh fcorrelation fbetween fthe fdose fand fsaturation fof freceptor fsites
D. To fdetermine fif fa fdrug fis fin fthe ftherapeutic frange
ANS: f D PTS: f 1
9. A flaboratory fresult findicates fthe fpeak flevel ffor fa fdrug fis fabove fthe
fminimum ftoxic fconcentration. fThis f means fthat fthe:
A. Concentration fwill fproduce ftherapeutic feffects
B. Concentration fwill fproduce fan fadverse fresponse
C. Time fbetween fdoses fmust fbe fshortened
D. Duration fof faction fof fthe fdrug fis ftoo flong
ANS: f B PTS: f 1
10. Drugs fthat fare freceptor fagonists fmay fdemonstrate fwhat fproperty?
A. Irreversible fbinding fto fthe fdrug freceptor fsite
B. Up-regulation fwith fchronic fuse
C. Desensitization for fdown-regulation fwith fcontinuous fuse
D. Inverse frelationship fbetween fdrug fconcentration fand fdrug faction
ANS: f C PTS: f 1
11. Drugs fthat fare freceptor fantagonists, fsuch fas fbeta fblockers, fmay fcause:
A. Down-regulation fof fthe fdrug freceptor
B. An fexaggerated fresponse fif fabruptly fdiscontinued
C. Partial fblockade fof fthe feffects fof fagonist fdrugs
D. An fexaggerated fresponse fto fcompetitive fdrug fagonists
ANS: f B PTS: f 1
12. Factors fthat faffect fgastric fdrug fabsorption finclude:
A. Liver fenzyme factivity
B. Protein-binding fproperties fof fthe fdrug fmolecule
C. Lipid fsolubility fof fthe fdrug
D. Ability fto fchew fand fswallow
ANS: f C PTS: f 1
, lOMoAR cPSD| 21007614
13. Drugs fadministered fvia fintravenous f(IV) froute:
A. Need fto fbe flipid fsoluble fin forder fto fbe feasily fabsorbed
B. Begin fdistribution finto fthe fbody fimmediately
C. Are feasily fabsorbed fif fthey fare fnonionized
D. May fuse fpinocytosis fto fbe fabsorbed
ANS: f B PTS: f 1
14. When fa fmedication fis fadded fto fa fregimen ffor fa fsynergistic feffect, fthe fcombined
feffect fof fthe fdrugs f is:
A. The fsum fof fthe feffects fof feach fdrug findividually
B. Greater fthan fthe fsum fof fthe feffects fof feach fdrug findividually
C. Less fthan fthe feffect fof feach fdrug findividually
D. Not fpredictable, fas fit fvaries fwith feach findividual
ANS: f B PTS: f 1
15. Which fof fthe ffollowing fstatements fabout fbioavailability fis ftrue?
A. Bioavailability fissues fare fespecially fimportant ffor fdrugs fwith fnarrow
ftherapeutic franges for fsustained frelease f mechanisms.
B. All fbrands fof fa fdrug fhave fthe fsame fbioavailability.
C. Drugs fthat fare fadministered fmore fthan fonce fa fday fhave fgreater
fbioavailability fthan fdrugs fgiven fonce fdaily.
D. Combining fan factive fdrug fwith fan finert fsubstance fdoes fnot faffect fbioavailability.
ANS: f A PTS: f 1
16. Which fof fthe ffollowing fstatements fabout fthe fmajor fdistribution fbarriers f(blood-
brain for ffetal-placental) fis ftrue?
A. Water fsoluble fand fionized fdrugs fcross fthese fbarriers frapidly.
B. The fblood-brain fbarrier fslows fthe fentry fof fmany fdrugs finto fand ffrom fbrain fcells.
C. The ffetal-placental fbarrier fprotects fthe ffetus ffrom fdrugs ftaken fby fthe fmother.
D. Lipid fsoluble fdrugs fdo fnot fpass fthese fbarriers fand fare fsafe ffor fpregnant fwomen.
ANS: f B PTS: f 1
17. Drugs fare fmetabolized fmainly fby fthe fliver fvia fPhase fI for fPhase fII freactions. fThe
fpurpose fof fboth fof fthese ftypes fof freactions f is f to:
A. Inactivate fprodrugs fbefore fthey fcan fbe factivated fby ftarget ftissues
B. Change fthe fdrugs fso fthey fcan fcross fplasma fmembranes
C. Change fdrug fmolecules fto fa fform fthat fan fexcretory forgan fcan fexcrete
D. Make fthese fdrugs fmore fionized fand fpolar fto ffacilitate fexcretion
ANS: f C PTS: f 1
18. Once fthey fhave fbeen fmetabolized fby fthe fliver, fthe fmetabolites fmay fbe:
A. More factive fthan fthe fparent fdrug
B. Less factive fthan fthe fparent fdrug
C. Totally f“deactivated” fso fthat fthey fare fexcreted fwithout fany feffect
D. All fof fthe fabove
ANS: f D PTS: f 1
